Sarepta Therapeutics Cash Flow - Quarterly (NASDAQ:SRPT)

Add to My Stocks
$42.54 $1.41 (3.21%) SRPT stock closing price Jul 25, 2017 (Closing)

The financial analysis of SRPT requires an investor to check the cash flows for Sarepta Therapeutics. This report provides details about cash inflows and outflows due to the company's business and investment activities, and summarize cash outflows for a given quarter. For Sarepta Therapeutics profits one has to check the income statement and for Sarepta Therapeutics debt one has to check the balance sheet. Items like capital purchases, bank loan payments etc. which have a direct impact on the cash position of a company come out through the statemement of cash flows and help an investor who undertakes the Sarepta Therapeutics stock analysis. Sarepta Therapeutics generated $-57.88M cash from operating activities in 2017-Q1. The cash from operating activities for Sarepta Therapeutics is $-57.88M for 2017-Q1, which saw an increase of -76.45% from previous quarter. View details of Sarepta Therapeutics cash flows for latest & last 40 quarters.

show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec. 2017-Q1 2016-Q4 2016-Q3 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3
Sarepta Therapeutics Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow1.61M5.69M4.42M1.63M5.89M4.68M3.18M1.59M6.12M4.34M
Net Increase (Decrease) in Assets Liabilities-24.79M-15.76M-13.83M-9.4M31.98M6.51M8.12M2.32M-22.13M-33.5M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net-118.8M31.52M23.64M6.85M32.68M25.94M20.21M14.28M23.26M17.44M
Sarepta Therapeutics Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-4.46M-5.34M-2.42M-1.16M-3.4M-2.31M-1.16M-0.53M-25.44M-22.3M
Acquisition Disposition of Subsidiaires----------
Increase (Decrease) in Investments90.69M-83.32M112.1M21M13.24M81.52M49.01M44.75M-132.2M-182.34M
Other Cash Inflow (Outflow) from Investment Activities123.75M-1.52M-1.09M-0.41M-1.43M-0.98M-0.64M-0.39M-1.38M-1.06M
Sarepta Therapeutics Net Cash from (used by) Invesment Activities
Issuance (Purchase) of Equity Shares2.74M385.73M375.91M1.48M130.8M5.2M0.97M0.43M104.24M104.2M
Issuance (Repayment) of Debt Securities-2.54M-7.6M-5.07M-2.52M17M17.02M19.68M-0.02M-0.09M-0.07M
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities----------
Sarepta Therapeutics Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash----------
Sarepta Therapeutics Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year80.3M73.55M256.96M39.9M33.58M48.27M11.19M24.8M20.15M34.59M
Cash & Equivalents at Year End274.85M122.42M395.14M38M80.3M55.81M69.53M74.43M73.55M52.29M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters
Get Cash flow for another ticker

Sarepta Therapeutics stock comparison chart provides an easy way to compare the stock price with peers along with details of Sarepta Therapeutics stock price history.
The statement of cash flows can be categorized into three main sections:
  • Net Change in Cash and Cash Equivalents: Sarepta Therapeutics cash grew QoQ to $84.09M, meaning the company is able to meet its expenditure and grow cash which will also eventually reflect in the Sarepta Therapeutics stock price movement.
  • Sarepta Therapeutics increased its cash from operating activities to $187.94M in 2017-Q1. Operating activities include production of goods or creating a product or providing a service, and collecting payment for the same from customers. The cash generated from these activities is refered to as cash flow from operating activities.
  • Growth companies (typically most tech companies) spend heavily  on investing activities and this figure was positive at $209.98M for SRPT stock. Sometimes a company might have a negative overall cash flow which may not be really bad if it is due to investment expenses. Hence it is important to check the cash flow from investment activities.
  • Cash Flow from financing activities: The cash inflow/outflow from financing activities was $0.2M for Sarepta Therapeutics. The money accounted for under this head comes from external sources which includes lenders, investors and shareholders. Positive cash flow is generated when the company gets cash because of issuance of stocks or bonds. Similarly negative cash flow is generated when shares are repurchased, dividend payments are made, and loans or interest on loans are paid back.

Key Financial Ratios For Sarepta Therapeutics Cash Flow

FCF margin